There’s been an explosion in the development of immunotherapies and the class is rapidly changing treatment paradigms and improving clinical outcomes. Via a new web-based platform, CancerLandscape™, we take an in-depth look at the I-O landscape i...
We report on three high profile initiatives in precision medicine that were highlighted at ASCO 2015: the NCI-Match trial, ASCO’s TAPUR trial and CancerLinQ. OBR talks to some leading cancer researchers involved in the trials and reports on their ...
Oncology brands and their marketers today face the challenge of quickly plateauing drug sales as soon as 12 to 18 months after launch. We look at what’s driving the change and propose four actionable "levers" to try and reverse that trend and grow...